Jeena Sikho Lifecare Limited Board Meeting Outcome: Internal Auditor Changes

2 min read     Updated on 23 Dec 2025, 08:12 PM
scanx
Reviewed by
Riya DScanX News Team
Overview

Jeena Sikho Lifecare Limited conducted a board meeting on December 23, 2025, approving the resignation of M/s Deepak K Garg Associates as Internal Auditor and appointing M/s. Forvis Mazars LLP for FY 2025-26. The transition ensures continuity in internal audit processes while maintaining regulatory compliance with SEBI requirements.

28045882

*this image is generated using AI for illustrative purposes only.

Jeena Sikho Lifecare Limited's Board of Directors conducted a meeting on December 23, 2025, at the company's registered office in Mohali, Punjab, to address significant changes in its internal audit structure. The board meeting, which commenced at 7:00 PM and concluded at 7:15 PM, focused on the transition of internal audit responsibilities.

Internal Auditor Resignation

The board formally accepted the resignation of M/s Deepak K Garg Associates, Chartered Accountants, from their position as Internal Auditor. The resignation was submitted via email on December 23, 2025, with the auditor citing pre-occupation with other professional commitments as the primary reason for stepping down.

Parameter: Details
Outgoing Auditor: M/s Deepak K Garg Associates
Representative: CA. Puneet Gupta
Resignation Date: December 23, 2025
Reason: Pre-occupation with other professional commitments

The internal auditor confirmed that there were no material reasons for resignation other than those mentioned in the resignation communication. CA. Puneet Gupta, representing the firm, expressed gratitude for the opportunity and cooperation received during the tenure.

New Internal Auditor Appointment

Simultaneously, the board approved the appointment of M/s. Forvis Mazars LLP as the new Internal Auditor for the Financial Year 2025-26. The appointment ensures continuity in the company's internal audit processes and compliance requirements.

Parameter: Details
New Auditor: M/s. Forvis Mazars LLP
Representative: Mr. Sunil Kalra
Appointment Date: December 23, 2025
Term: One year (FY 2025-26)

M/s. Forvis Mazars LLP is described as a leading international assurance, tax, and advisory firm that assists clients in achieving sustainable and responsible growth. The firm serves a wide range of industries with strong sector-specific understanding and offers a diverse portfolio of services that enhances the relevance and quality of its offerings.

Regulatory Compliance

The board meeting outcomes were communicated to both the National Stock Exchange of India Limited and BSE Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided detailed annexures containing additional disclosures as required under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The transition reflects the company's commitment to maintaining robust internal audit practices while ensuring compliance with regulatory requirements. The appointment of an established international firm demonstrates the company's focus on strengthening its governance framework for the upcoming financial year.

Historical Stock Returns for Jeena Sikho Lifecare

1 Day5 Days1 Month6 Months1 Year5 Years
-3.06%-1.27%-15.19%-25.87%-63.82%+251.11%

Jeena Sikho Lifecare Secures Exchange Approval for ESOP, Appoints New COO

1 min read     Updated on 10 Dec 2025, 08:16 PM
scanx
Reviewed by
Radhika SScanX News Team
Overview

Jeena Sikho Lifecare Limited has secured regulatory approvals from NSE and BSE for its Employee Stock Option Scheme 2025, covering up to 2,50,000 equity shares. The company also appointed Sahil Jain as COO and promoted Shreya Grover to Whole-Time Director, alongside approving a final dividend of ₹1.10 per share.

17844030

*this image is generated using AI for illustrative purposes only.

Jeena Sikho Lifecare Limited has announced a series of significant developments, including receiving regulatory approvals for its Employee Stock Option Scheme and key leadership changes, positioning the company for strategic growth in the healthcare sector.

Stock Exchange Approvals for ESOP Scheme

The company has received crucial in-principle approvals from both major stock exchanges for its Employee Stock Option Scheme 2025. The approvals cover the listing of up to 2,50,000 equity shares of ₹2.00 each under the scheme.

Exchange: Reference Number Approval Date
NSE: NSE/LIST/51687 December 9, 2025
BSE: DCS/ESOP/IP/RG/3955/2025-26 December 10, 2025

These approvals represent a significant milestone following the Board's initial approval of the ESOP scheme on August 27, 2025. The scheme aims to benefit eligible employees and directors across the company and its group entities.

Leadership Appointments and Changes

The company appointed Sahil Jain as its new Chief Operating Officer, effective August 27, 2025. Jain brings over eight years of experience within the organization, having previously led key departments including IT, Marketing, Call Center Operations, and Administration. His background includes valuable experience at global technology firms IBM and HCL Australia.

In a significant board restructuring, Shreya Grover has been redesignated from Non-Executive Director to Whole-Time Director for a five-year term. Grover, daughter of Managing Director Manish Grover and associated with the company since June 2021, will focus on guiding growth strategies, including Ayurveda hospital expansion and OTC Ayurveda product launches.

Corporate Governance and Financial Decisions

The Board made several other strategic decisions during its August meeting:

Decision: Details
Secretarial Auditor: Ankur Singh & Associates appointed for FY 2025-26 to FY 2029-30
Annual General Meeting: Scheduled for September 29, 2025
Final Dividend: ₹1.10 per equity share for FY ended March 31, 2025

These developments indicate the company's commitment to strengthening its operational framework while rewarding stakeholders through dividend distributions and employee participation schemes.

Strategic Positioning

The combination of regulatory approvals for the ESOP scheme, strategic leadership appointments, and governance enhancements suggests Jeena Sikho Lifecare is positioning itself for expansion in the Ayurveda and wellness sector. The company's focus on employee retention through stock options and operational efficiency through experienced leadership appointments demonstrates a comprehensive approach to sustainable growth.

Historical Stock Returns for Jeena Sikho Lifecare

1 Day5 Days1 Month6 Months1 Year5 Years
-3.06%-1.27%-15.19%-25.87%-63.82%+251.11%

More News on Jeena Sikho Lifecare

1 Year Returns:-63.82%